Literature DB >> 17886255

Signaling by estrogens.

Boris J Cheskis1, James G Greger, Sunil Nagpal, Leonard P Freedman.   

Abstract

By regulating activities and expression levels of key signaling molecules, estrogens control mechanisms that are responsible for crucial cellular functions. Ligand binding to estrogen receptor (ER) leads to conformational changes that regulate the receptor activity, its interaction with other proteins and DNA. In the cytoplasm, receptor interactions with kinases and scaffolding molecules regulate cell signaling cascades (extranuclear/nongenomic action). In the nucleus, estrogens control a repertoire of coregulators and other auxiliary proteins that are associated with ER, which in turn determines the nature of regulated genes and level of their expression (genomic action). The combination of genomic and nongenomic actions of estrogens ultimately confers the cell-type and tissue-type selectivity. Recent studies have revealed some important new insights into the molecular mechanisms underlying ER action, which may help to explain the functional basis of existing selective ER modulators (SERMs) and provide evidence into how ER might be selectively targeted to achieve specific therapeutic goals. In this review, we will summarize some new molecular details that relate to estrogen signaling. We will also discuss some new strategies that may potentially lead to the development of functionally selective ER modulators that can separate between the beneficial, prodifferentiative effects in bone, the cardiovascular system and the CNS as well as the "detrimental," proliferative effects in reproductive tissues and organs. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17886255     DOI: 10.1002/jcp.21253

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  77 in total

1.  Functional variable number of tandem repeats variation in the promoter of proto-oncogene PTTG1IP is associated with risk of estrogen receptor-positive breast cancer.

Authors:  Chan Xiang; Haidong Gao; Lei Meng; Zhaoyu Qin; Rong Ma; Yang Liu; Yan Jiang; Chengxue Dang; Li Jin; Fuchu He; Haijian Wang
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

Review 2.  The developmental origins of the mammalian ovarian reserve.

Authors:  Kathryn J Grive; Richard N Freiman
Journal:  Development       Date:  2015-08-01       Impact factor: 6.868

3.  Tumor suppressor function of RUNX3 in breast cancer.

Authors:  Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

Review 4.  Endocrine regulation of lung disease and inflammation.

Authors:  Nathalie Fuentes; Patricia Silveyra
Journal:  Exp Biol Med (Maywood)       Date:  2018-12-03

5.  Expression of an estrogen receptor agonist in differentiating osteoblast cultures.

Authors:  Thomas L McCarthy; Mary E Clough; Caren M Gundberg; Michael Centrella
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-12       Impact factor: 11.205

6.  Estrogen receptor-alpha as a drug target candidate for preventing lung inflammation.

Authors:  Elisabetta Vegeto; Salvatore Cuzzocrea; Concetta Crisafulli; Emanuela Mazzon; Angelo Sala; Andreè Krust; Adriana Maggi
Journal:  Endocrinology       Date:  2009-12-01       Impact factor: 4.736

Review 7.  Estrogen and the female heart.

Authors:  A A Knowlton; D H Korzick
Journal:  Mol Cell Endocrinol       Date:  2014-01-22       Impact factor: 4.102

Review 8.  Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels.

Authors:  Dia A Smiley; Raouf A Khalil
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

9.  Estrogen regulation of TRPM8 expression in breast cancer cells.

Authors:  Dechen Chodon; Arnaud Guilbert; Isabelle Dhennin-Duthille; Mathieu Gautier; Marie-Sophie Telliez; Henri Sevestre; Halima Ouadid-Ahidouch
Journal:  BMC Cancer       Date:  2010-05-19       Impact factor: 4.430

Review 10.  Osteoarthritis associated with estrogen deficiency.

Authors:  Jorge A Roman-Blas; Santos Castañeda; Raquel Largo; Gabriel Herrero-Beaumont
Journal:  Arthritis Res Ther       Date:  2009-09-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.